Current Cardiology Reports

, 15:386 | Cite as

Patients with Chronic Kidney Disease/Diabetes Mellitus: The High-Risk Profile in Acute Coronary Syndrome

Management of Acute Coronary Syndromes (R Mehran, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Management of Acute Coronary Syndromes

Abstract

Chronic kidney disease (CKD) and diabetes mellitus (DM) are highly prevalent, morbid diseases that are very common among patients presenting with acute coronary syndromes (ACS). Despite significant reductions in cardiovascular morbidity and mortality over the last half century, residual vascular risk remains disproportionately high in these populations. In large part, this is attributable to pre-existing vascular morbidity and substantial enrichment of traditional risk factors among those with either CKD or DM. Other factors, such as less aggressive therapeutic intervention and a unique atherothrombotic phenotype, are also contributory. The introduction of novel antiplatelet and antithrombotic agents over the last several years provides fresh opportunities to improve the adverse prognosis among patients with CKD or DM and concomitant ACS.

Keywords

Diabetes mellitus Chronic kidney disease Acute coronary syndrome 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance

  1. 1.
    Herrick JB. Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By James B. Herrick. JAMA. 1983;250(13):1757–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Julian DG. Treatment of cardiac arrest in acute myocardial ischaemia and infarction. Lancet. 1961;2(7207):840–4.PubMedCrossRefGoogle Scholar
  3. 3.
    •• Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1):54–63. This review is a well-written comprehensive summary of significant innovations and advances in cardiovascular medicine during the 20th century. PubMedCrossRefGoogle Scholar
  4. 4.
    Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Goble AJ, Sloman G, Robinson JS. Mortality reduction in a coronary care unit. Br Med J. 1966;1(5494):1005–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388–98.PubMedCrossRefGoogle Scholar
  7. 7.
    Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.PubMedCrossRefGoogle Scholar
  8. 8.
    Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32(2):287–94.PubMedCrossRefGoogle Scholar
  9. 9.
    •• Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–65. This report provides a detailed contemporary assessment of acute coronary syndrome management in patients with chronic kidney disease. PubMedCrossRefGoogle Scholar
  10. 10.
    Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004;164(13):1457–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Centers for disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for diseae Control and Prevention; 2011.Google Scholar
  12. 12.
    US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal disease. Bethesda, MD: National INstitutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2012.Google Scholar
  13. 13.
    Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRefGoogle Scholar
  15. 15.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Mehran R, Nikolsky E, Lansky AJ, et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009;2(8):748–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J. 1976;38(7):659–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006;47(3):378–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Acharya DU, Shekhar YC, Aggarwal A, Anand IS. Lack of pain during myocardial infarction in diabetics–is autonomic dysfunction responsible? Am J Cardiol. 1991;68(8):793–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Chiariello M, Indolfi C, Cotecchia MR, et al. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J. 1985;110(3):529–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Fergus TS, Fazel R, Fang J, et al. Presentation, management, and outcomes of diabetic patients compared to non-diabetic patients admitted for acute coronary syndromes. Heart. 2004;90(9):1051–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med. 2006;119(3):248–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153(1):29–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Baber U, Mann D, Shimbo D, et al. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol. 2009;104(10):1446–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Nagashima M, Hagiwara N, Koyanagi R, et al. Chronic kidney disease and long-term outcomes of myocardial infarction. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.04.049.
  28. 28.
    Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis. 2010;21(6):336–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Motivala AA, Cannon CP, Srinivas VS, et al. Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011;58(17):1760–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303(21):2156–64.PubMedCrossRefGoogle Scholar
  31. 31.
    Norhammar A, Lindback J, Ryden L, et al. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 2007;93(12):1577–83.PubMedCrossRefGoogle Scholar
  32. 32.
    Gitt AK, Schiele R, Wienbergen H, et al. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. Acta Diabetol. 2003;40 Suppl 2:S343–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77(1):126–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166(17):1884–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Singla A, Antonino MJ, Bliden KP, et al. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J. 2009;158(5):784.e1–6.Google Scholar
  36. 36.
    Leblond F, Guevin C, Demers C, et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12(2):326–32.PubMedGoogle Scholar
  37. 37.
    Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int. 1993;44(2):445–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Sagripanti A, Cupisti A, Baicchi U, et al. Plasma parameters of the prothrombotic state in chronic uremia. Nephron. 1993;63(3):273–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Baber, U.: Independent and Combined Impact of Diabetes Mellitus and Chronic Kidney Disease on Platelet Reactivity. Presented at ACC Scientific Sessions, New Orleans LA, 2011.Google Scholar
  40. 40.
    Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118(12):1416.PubMedCrossRefGoogle Scholar
  41. 41.
    Barazzoni R, Zanetti M, Davanzo G, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab. 2000;85(9):3121–5.PubMedCrossRefGoogle Scholar
  42. 42.
    King DE, Mainous 3rd AG, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26(5):1535–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Rauch U, Crandall J, Osende JI, et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol. 2000;86(2):246–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38(5):1307–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Baber, U.: Physiologic Impact of Chronic Kidney Disease on Whole Blood Clot Kinetics and Strength. Presented at ACC Scientific Sessions, Chicago IL, 2012.Google Scholar
  46. 46.
    Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14(2):312–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Mather AN, Crean A, Abidin N, et al. Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:61.PubMedCrossRefGoogle Scholar
  48. 48.
    Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1(8478): 397-402.Google Scholar
  49. 49.
    Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607): 349-360.Google Scholar
  50. 50.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319(17):1105–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83.PubMedCrossRefGoogle Scholar
  52. 52.
    Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875–910.PubMedCrossRefGoogle Scholar
  53. 53.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.PubMedCrossRefGoogle Scholar
  54. 54.
    Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–36.PubMedCrossRefGoogle Scholar
  55. 55.
    James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006–16.PubMedCrossRefGoogle Scholar
  56. 56.
    James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.PubMedCrossRefGoogle Scholar
  57. 57.
    Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation. 2010;122(11):1049–52.PubMedCrossRefGoogle Scholar
  58. 58.
    Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis. 1994;24(2):105–17.PubMedGoogle Scholar
  59. 59.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477–88.PubMedCrossRefGoogle Scholar
  61. 61.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447–52.PubMedCrossRefGoogle Scholar
  62. 62.
    Morrow DA, Antman EM, Murphy SA, et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J. 2007;154(6):1078–84. 1084 e1071.PubMedCrossRefGoogle Scholar
  63. 63.
    Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49(23):2249–55.PubMedCrossRefGoogle Scholar
  64. 64.
    Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001;119(1 Suppl):95S–107S.PubMedCrossRefGoogle Scholar
  65. 65.
    Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–76.PubMedCrossRefGoogle Scholar
  66. 66.
    Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007;147(5):304–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S–203S.PubMedCrossRefGoogle Scholar
  68. 68.
    Weitz JI, Bates SM. Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol. 2002;14(Suppl B):2B–7B.PubMedGoogle Scholar
  69. 69.
    Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203–16.PubMedCrossRefGoogle Scholar
  70. 70.
    Witzenbichler B, Mehran R, Guagliumi G, et al. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2011;4(7):760–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55(22):2435–45.PubMedCrossRefGoogle Scholar
  72. 72.
    • O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012;60(2):106–11. This pooled analysis evaluates the benefits of an early invasive versus conservative management approach in diabetic patients with acute coronary syndromes. PubMedCrossRefGoogle Scholar
  73. 73.
    Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4(6):1032–43.PubMedCrossRefGoogle Scholar
  74. 74.
    Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120(10):851–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.The Zena and Michael A. Wiener Cardiovascular InstituteThe Icahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations